

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Regenerative Medicine International Limited

中國再生醫學國際有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8158)

(1) CHANGE OF COMPANY SECRETARY AND (2) CHANGE OF AUTHORISED REPRESENTATIVE

The Board hereby announces that with effect from 6 January 2019:

- (i) Mr. Cheng Chai Fu will resign as the company secretary and the authorised representative of the Company; and
- (ii) Mr. Ip Wing Nin Clifford will be appointed as the company secretary and the authorised representative of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of China Regenerative Medicine International Limited (the “**Company**”) announces the following changes to member of the senior management and authorised representative of the Company for the purpose of Rule 5.24 of the Rules Governing the Listing of Securities on GEM made by The Stock Exchange of Hong Kong Limited (the “**Authorised Representative**”), with effect from 6 January 2019:

A. CHANGE OF COMPANY SECRETARY OF THE COMPANY

Following resignation of Mr. Cheng Chai Fu (“**Mr. Cheng**”) as the company secretary of the Company, Mr. Ip Wing Nin Clifford (“**Mr. Ip**”) will be appointed as the company secretary of the Company with effect from 6 January 2019.

Mr. Ip graduated from the University of Technology in Sydney, Australia, with a Bachelor of Laws degree. He is a member of The Law Society of Hong Kong, and a corporate/commercial lawyer qualified to practice law in Hong Kong with extensive experience in the areas of general commercial, corporate finance and company secretarial work.

B. CHANGE OF AUTHORISED REPRESENTATIVE OF THE COMPANY

Following resignation of Mr. Cheng as the authorised representative, Mr. Ip will be appointed as the Authorised Representative of the Company with effect from 6 January 2019.

The Board would like to take this opportunity to express its gratitude to Mr. Cheng for his valuable contributions to the Company during his tenure of service and express its warm welcome to Mr. Ip for his new roles in the Company.

By order of the Board
China Regenerative Medicine International Limited
Ray Yip
Chairman and Executive Director

Hong Kong, 4 January 2019

As at the date of this announcement, the executive Directors are Dr. Ray Yip (Chairman) and Mr. Wang Xuejun (Chief Executive Officer); and the independent non-executive Directors are Mr. Chan Bing Woon, SBS, JP, Mr. Wong Yiu Kit Ernest and Dr. Fang Jun.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcement” page of the GEM website at www.hkgem.com for at least seven days from the date of the publication and will be published on the website of the Company at www.crimi.hk.